An easy-to-store covid vaccination under development in NZ could be a boon for poorer nations.
The long-term effects must be carefully studied. But the excitement is justified.
The listed company has had its product approved for use in the multibillion-dollar US painkiller market.
NZ health is focusing on things that make little difference.